Surgery after multimodatity treatment for non-small-cell lung cancer

被引:26
作者
Stamatis, G
Eberhard, W
Pöttgen, C
机构
[1] Ruhrlandklin, Dept Thorac Surg & Endoscopy, D-45239 Essen, Germany
[2] Univ Essen Med Sch, W German Canc Ctr, Dept Internal Med, D-45122 Essen, Germany
[3] Univ Essen Med Sch, W German Canc Ctr, Dept Radiotherapy & Radiooncol, D-45122 Essen, Germany
关键词
advanced NSCLC; induction chemoradiotherapy; perioperative course; long-term survival;
D O I
10.1016/j.lungcan.2004.07.984
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoadjuvant treatment for locally advanced non-small-cell lung cancer (NSCLC) stage IIIA and IIIB promises higher resection rates because of a reduction of the primary tumour and sterilisation of mediastinal nodes ("downstaging"). In this study we analyse the perioperative course and the long-term survival of patients with trimodality treatment. Between 03/1991 and 12/2002, 392 patients with NSCLC underwent resection after induction treatment. Included were 266 mates and 126 females, age 55.8+/-9 (28-74), of whom 218 were stage-IIIA patients, 174 were stage-IIIB patients. Induction treatment included 3 courses of chemotherapy with cisplatin/etoposide or cisplatin/pactitaxel,followed by one course of chemotherapy with cisptatin/etoposide as well as hyperfractionated accelerated radiotherapy of the primary tumour and the mediastinal nodes with 45 Gy, followed by surgery. Before induction treatment all patients underwent mediastinoscopy. In patients with N3 disease mediastinoscopy was repeated before surgery. Resections included 133 pneumonectomies (34%), 15 bilobectomies (4%), 55 sleeve lobectomies (14%), 168 lobectomies (42.5%), 6 segmentectomies (1.5%), and 15 explorative thoracotomies (4%). In-hospital mortality rates amounted to 4.6% (18 patients) while postoperative morbidity ran up to 46% (180 patients). Morbidity and mortality rates were significantly higher in patients with Karnofsky status lower than 80% and patients older than 65 years. Bronchopleural fistulas occurred in 16 patients (3.2%). The protection of the bronchial stump or anastomosis with viable tissue, like pericardial fat, proves to be a significant factor for the reduction of septic complications. For NSCLC, the 5- and 7-year survival rates were 36% and 31%, respectively, for stage IIIA, and 26% for stage IIIB. This intensive trimodality treatment proves to be feasible. Treatment-related toxicities are overall moderate and acceptable. Accurate cardiopulmonary evaluation before surgery and reinforcement of bronchial stump or anastomosis can contribute to reducing complications. Induction treatment demonstrated a "downstaging effect", so that a clear trend for organ-sparing resection was observed. Long-term survival rates for selected groups took very promising when compared to historical controls. (C) 2004 Elsevier Science Ltd.
引用
收藏
页码:S107 / S112
页数:6
相关论文
共 24 条
[1]  
ABOLHODA A, 2001, 37 ANN M STS, P232
[2]  
ALBAIN KS, 1988, CARDIOVASC SURG, V102, P16
[3]  
ALBAIN KS, 2000, LUNG CANC PRINCIPLES, P798
[4]   Pneumonectomy for malignant disease: Factors affecting early morbidity and mortality [J].
Bernard, A ;
Deschamps, C ;
Allen, MS ;
Miller, DL ;
Trastek, VF ;
Jenkins, GD ;
Pairolero, PC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (06) :1076-1081
[5]   Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer [J].
Choi, NC ;
Carey, RW ;
Daly, W ;
Mathisen, D ;
Wain, J ;
Wright, C ;
Lynch, T ;
Grossbard, M ;
Grillo, H .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :712-722
[6]   Empyema and bronchopleural fistula after pneumonectomy: Factors affecting incidence [J].
Deschamps, C ;
Bernard, A ;
Nichols, FC ;
Allen, MS ;
Miller, DL ;
Trastek, VF ;
Jenkins, GD ;
Pairolero, PC .
ANNALS OF THORACIC SURGERY, 2001, 72 (01) :243-247
[7]   Postoperative complications in relation with induction therapy for lung cancer [J].
Doddoli, C ;
Thomas, P ;
Thirion, X ;
Serée, Y ;
Giudicelli, R ;
Fuentes, P .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2001, 20 (02) :385-390
[8]   Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer:: Mature results of a phase II trial [J].
Eberhardt, W ;
Wilke, H ;
Stamatis, G ;
Stuschke, M ;
Harstrick, A ;
Menker, H ;
Krause, B ;
Müeller, MR ;
Stahl, M ;
Flasshove, M ;
Budach, V ;
Greschuchna, D ;
Konietzko, N ;
Sack, H ;
Seeber, S .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :622-634
[9]  
FABRICE A, 1999, P AM SOC CLIN ONCOL, V18
[10]   POSTOPERATIVE COMPLICATIONS AFTER COMBINED NEOADJUVANT TREATMENT OF LUNG-CANCER [J].
FOWLER, WC ;
LANGER, CJ ;
CURRAN, WJ ;
KELLER, SM .
ANNALS OF THORACIC SURGERY, 1993, 55 (04) :986-989